Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?

• DOI: 10.1111/jog.14038
• Publication Date: 2019-08-29T12:43:34Z
• Authors: Kewei Zhang; Monica Zen; Nicole L. Popovic; Vincent W. Lee; Thushari I. Alaha...
• Keywords: Adult; Fetal Growth Retardation; Vascular Endothelial Growth Factor Receptor-1; Reproducibility of Results; 3. Good health; 03 medical and health sciences; Cross-Sectional Studies; 0302 clinical medicine; Pre-Eclampsia; Pregnancy; Case-Control Studies; Prenatal Diagnosis; Humans; Female; Biomarkers; Placenta Growth Factor

Abstract Aim To correlate plasma and urinary soluble fms‐like tyrosine kinase 1 (sFlt‐1) placental growth factor (PIGF) in preeclampsia (PE) fetal restriction (FGR) assess the performance detecting established disease. Methods A cross‐sectional case–control study recruited 26–40 weeks gestation pregnancies into four clinical groups: normal pregnancy, PE, PE + FGR, FGR. enzyme‐linked immunosorbent assay (ELISA) measurements of sFlt‐1 PlGF levels were performed. Urinary PIGF normalized to creatinine. Spearman's rank correlation was used association between PIGF, receiver operating characteristic graphs quantify each individual marker their ratios predicting versus pathological affected by and/or Results There a significant ( r = 0.718, P < 0.001) all groups. In groups, as well sFlt‐1: ratio higher, but lower when compared pregnancy. Plasma comparable for diagnosis Conclusion can be an alternative circulating biomarkers sFlt‐1, differentiate pregnancy complicated